The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study

Journal of Clinical Psychiatry

Volumn 60, Issue 4, 1999, Pages 232-236

  Zarate Jr , Carlos A ^c,d,e   Tohen, Mauricio ^a,b,d,e   Narendran, Rajesh ^d   Tomassini, Eric C ^d   McDonald, Jane ^d   Sederer, Max ^d   Madrid, Alex R ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL RECORD; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

EID: 0344889130     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0405     Document Type: Article

References (31)

1. Lambert PA, Caraz G, Borselli S, et al. Action neuro-psychotrope d'un nouvel antiepileptique: le depamide. Ann Med Psychol 1966;1:707-710
2. Hassan MN, Lajee HCK, Parsonage MJ. Sodium valproate in the treatment of resistant epilepsy. Acta Neurol Scand 1976;54:209-218
3. Bruni J, Wilder BJ. Valproic acid: review of a new antiepileptic drug. Arch Neurol 1979;36:393-398
4. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. JAMA 1980;244:785-788
5. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:395-405
6. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48: 62-68
7. Bowden CL, Brugger AM, Swann AC. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
8. Schmidt D. Adverse effects of valproate. Epilepsia 1984;25(suppl 1): S44-S49
9. Tohen M. The adverse effect profile and safety of divalproex. Rev Contemp Pharmacother 1995;6:587-595
10. Espir MLE, Benton P, Hayes MJ, et al. Sodium valproate (Epilim). In: Legg NJ, ed. Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy. Tunbridge Wells, England: MCS Consultants; 1976:145-151
11. Jeavons PM, Clarke JE, Harding GFA. Valproate and curly hair [letter]. Lancet 1977;1:359
12. Batalden PB, Van Dyne BJ, Cloyd J. Pancreatitis associated with valproic acid therapy. Pediatrics 1979;64:520-522
13. Binek J, Hany A, Heer M. Valproic-acid-induced pancreatitis: case report and review of the literature. J Clin Gastroenterol 1991;13:690-693
14. Scheffner D. Fatal liver failure in children on valproate [letter]. Lancet 1986;2:511
15. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-385
16. Dreiffuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities, II: US experience since 1984. Neurology 1989;39:201-207
17. Sussman NM, McLain LW Jr. A direct hepatotoxic effect of valproic acid. JAMA 1979;242:1173-1174
18. Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979;5:389-390
19. Delgado MR, Rieta AR, Mills J, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994;9: 311-314
20. Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152:413-418
21. Noronha MJ, Bevan PLT. A literature review of unwanted effects of treatment with Epilim. In: Legg NJ, ed. Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy. Tunbridge Wells, England: MCS Consultants; 1976:61-65
22. Dinessen H, Gram L, Anderson T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69
23. Price DJE. The advantage of sodium valproate in neurosurgical practice. In: Legg NJ, ed. Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy. Tunbridge Wells, England: MCS Consultants; 1976:44-50
24. Hamilton RA, Garnett WR, Kline BJ, et al. Effects of food on valproic acid absorption. Am J Hosp Pharm 1981;38:1490-1493
25. McElroy SL, Keck PE Jr, Bennett JA. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146-149
26. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
27. Wilder BJ, Karas BJ, Penry JK, et al. Gastrointestinal tolerance of divalproex sodium. Neurology 1983;33:808-811
28. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
29. Zarate CA Jr, Narendran R, Tohen M, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-28
30. Marks WA, Morris MP, Bodensteiner JB, et al. Gastritis with valproate therapy. Arch Neurol 1988;45:903-905
31. Jamison KR, Gemer RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979;36: 866-869